Omnicell (OMCL) Net Income towards Common Stockholders (2010 - 2026)
Omnicell's (OMCL) quarterly Net Income towards Common Stockholders came in at $24.3 million in Q2 2026, up 330.73% year-over-year from $5.6 million in Q2 2025, and up 113.85% quarter-over-quarter from $11.4 million in Q1 2026.
Analysis
Omnicell (OMCL) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Omnicell (OMCL) has reported Net Income towards Common Stockholders for 17 consecutive years, with $24.3 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 330.73% year-over-year to $24.3 million in Q2 2026; TTM through Jun 2026 was $39.1 million, a 69.28% increase from a year earlier, with the FY2025 full-year figure at $2.1 million, down 83.62% from the prior year.
- Net Income towards Common Stockholders was $24.3 million for Q2 2026 at Omnicell, up from $11.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $24.3 million in Q2 2026 and troughed at -$28.4 million in Q4 2022.
- A 5-year average of $2.0 million and a median of $5.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders tumbled 303.23% in 2022 and surged 330.73% in 2026, its largest moves.
- Over 5 years, Net Income towards Common Stockholders stood at -$28.4 million in 2022, then soared by 49.41% to -$14.4 million in 2023, then soared by 210.21% to $15.8 million in 2024, then plunged by 112.79% to -$2.0 million in 2025, then surged by 1298.86% to $24.3 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $24.3 million (Q2 2026), $11.4 million (Q1 2026), and -$2.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | 907.00 Mn |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | - |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn | 383.43 Mn |
| 10 | Omnicell | 1.57 Bn | 1.28 Bn | 152.94 Mn | 24.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.29 Mn |
| Mar 31, 2026 | 11.36 Mn |
| Dec 31, 2025 | -2.03 Mn |
| Sep 30, 2025 | 5.46 Mn |
| Jun 30, 2025 | 5.64 Mn |
| Mar 31, 2025 | -7.02 Mn |
| Dec 31, 2024 | 15.84 Mn |
| Sep 30, 2024 | 8.63 Mn |
| Jun 30, 2024 | 3.74 Mn |
| Mar 31, 2024 | -15.63 Mn |
| Dec 31, 2023 | -14.38 Mn |
| Sep 30, 2023 | 5.55 Mn |
| Jun 30, 2023 | 3.45 Mn |
| Mar 31, 2023 | -14.98 Mn |
| Dec 31, 2022 | -28.41 Mn |
| Sep 30, 2022 | 16.77 Mn |
| Jun 30, 2022 | 9.07 Mn |
| Mar 31, 2022 | 8.21 Mn |
| Dec 31, 2021 | 13.98 Mn |
| Sep 30, 2021 | 29.32 Mn |